Antibody–drug conjugates (ADCs) dominated several high‑profile sessions at ESMO, with multiple companies reporting combination strategies that pair ADCs with PD‑1 inhibitors or chemotherapies to broaden activity across tumor types. BioCentury and conference coverage highlighted new data presented by AstraZeneca, Merck and others showing activity in urothelial, breast and ovarian cancers. Speakers emphasized that ADCs are moving from salvage indications into earlier lines and combination regimens, shifting development strategies and partnership structures. Presentations stressed clinical endpoints, tolerability in combination, and biomarker strategies to select patients. Drug developers and oncology strategists will need to consider ADC sequencing, manufacturing scale, linker‑payload optimization and payer negotiation as more combination regimens read out in registrational programs.